Publications

Find out about the public submissions on scheduling matters referred to the ACMS, ACCS & Joint ACMS-ACCS MARCH, 2024

We conduct an annual stakeholder survey to improve the way we work with our stakeholders and help report on our key performance indicators.

The report includes data and feedback from the general public (consumers), people and organisations with a TGA business services account (opt-in stakeholders), and state and territory government representatives.

The Australian Sunscreen Exposure Model performs sunscreen exposure calculations that reflect the unique conditions and practices in Australia.

Read our business plan 2025-26 to find out about our strategic priorities and activities.

Documents released under the FOI Act in the 2024/25 financial year

Based on the data considered in this safety review, we recommend regulatory controls for homosalate and oxybenzone to restrict their permitted concentrations and use in therapeutic sunscreens.

This updated safety review uses the Australian Sunscreen Exposure Model to assess the risk of benzophenone as a degradant in sunscreens.

This Cost Recovery Implementation Statement (CRIS) 2025-2026 provides information on how we implement, and cost recover our regulatory activities.

Find out about the public submissions on scheduling matters referred to the ACMS #46 meeting held in November 2024

The report cards show the progress made by the TGA in the 3 strategies that make up the Action Plan for Medical Devices.

Find out about the public submissions on scheduling matters referred to the ACMS #47 meeting held in June 2025

Find out about the public submissions on scheduling matters referred to the ACMS #47 and Joint ACMS-ACCS #40 meetings held in June 2025

Find out about the seasonal influenza vaccines available for the 2025 southern hemisphere season.

Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).

Detailed statistical information on Therapeutic Goods Administration performance in pre- and post-market activities.

This report provides information about our regulatory performance for the 2023-24 financial year.

This report provides an overview of pharmacovigilance inspection deficiencies in 2022, including a comparison to results from previous reporting periods.

The findings will inform the need for any risk management actions to ensure public safety.

This plan outlines our compliance and education priorities for 2024-2025.

Read our 2024 stakeholder survey report, which aims to improve the way we work with our stakeholders.

We commissioned the Health Design Lab to conduct market research to better understand the individual consumer, pharmacist and prescriber experiences of shortages and discontinuations.

Find out about the public submissions on interim decisions for scheduling matters referred to the ACMS #44, ACCS #38 and Joint ACMS-ACCS #36 meetings held in March 2024

Read our business plan 2024-25 to find out about our strategic priorities and activities.

Find out how we are managing shortages of medicines and taking action to limit their effects. Read our 2024 report.

Find out about the public submissions on scheduling matters referred to the ACMS #44, ACCS #38 and Joint ACMS-ACCS #36 meetings held in March 2024